Core A (Administrative Core) will provide all the logistic, scientific, managerial, regulatory and financial support necessary to facilitate and coordinate the studies described in this Consortium. The Administrative Core will ensure that all common and project-specific efforts function optimally and adhere to the timelines described in Program Overview and in the individual projects of this proposal. The Core will organize conference calls every two weeks among Project leaders and other relevant personnel, facilitate regular in-person meetings, maintain regulatory approvals, provide fiscal and logistic oversight, and coordinate meetings with the Scientific Advisory Board and DAIDS Program Officials. The Core will also establish a Scientific Leadership Committee, the primary decision-making body of the Consortium, whose roles include determining allocations of primate resources to individual experiments and consulting in the design of these experiments. The Core will coordinate four annual meetings of this Leadership Committee. The Administrative Core and Scientific Leadership Committee will ensure that all the studies and resources are applied to the primary goals of this proposal. These are: ? to establish the therapeutic utility in HIV-1 infection of a cocktail of antibody or antibody-like entry inhibitors delivered through recombinant adeno-associated virus (AAV) vectors, and ? to identify principles, protocols, and therapeutics directly applicable to human clinical trials. We will support these goals in five Specific Aims: 1. To coordinate communications, interactions, and operations among investigators. Projects, and Cores to facilitate the overall progress and promote the goals of this program project. 2. To coordinate four annual meetings of the Scientific Leadership committee. 3. To ensure and maintain regulatory compliance. 4. To provide detailed financial oversight and management. 5. To coordinate meetings with the Scientific Advisory Board.

Public Health Relevance

The Administrative core is responsible for all fiscal, regulatory, and administrative aspects of this proposal. In addition, it will facilitate communication among Project Leaders, and organize meetings of the Leadership and Scientific Advisory Committees. These activities will promote the broad aim of this Program Project: to establish the therapeutic utility in an ongoing HIV-1 infection of specific cocktails of AAV-delivered antivirals.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RB-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Florida
United States
Zip Code
Wang, Dan; Li, Jia; Song, Chun-Qing et al. (2018) Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nat Biotechnol 36:839-842
Fetzer, Ina; Gardner, Matthew R; Davis-Gardner, Meredith E et al. (2018) eCD4-Ig Variants That More Potently Neutralize HIV-1. J Virol 92:
Yoon, Yeonsoo; Wang, Dan; Tai, Phillip W L et al. (2018) Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses. Nat Commun 9:412
Zhang, Wei; Li, Linjing; Su, Qin et al. (2018) Gene Therapy Using a miniCEP290 Fragment Delays Photoreceptor Degeneration in a Mouse Model of Leber Congenital Amaurosis. Hum Gene Ther 29:42-50
Tai, Phillip W L; Xie, Jun; Fong, Kaiyuen et al. (2018) Adeno-associated Virus Genome Population Sequencing Achieves Full Vector Genome Resolution and Reveals Human-Vector Chimeras. Mol Ther Methods Clin Dev 9:130-141
Mou, Huihui; Zhong, Guocai; Gardner, Matthew R et al. (2018) Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence. Mol Ther 26:1277-1286
Wang, Dan; Gao, Guangping (2018) Taking a Hint from Structural Biology: To Better Understand AAV Transport across the BBB. Mol Ther 26:336-338
Wang, Dan; Li, Jia; Tran, Karen et al. (2018) Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space. Hum Gene Ther Methods 29:75-85
Wang, Dan; Li, Shaoyong; Gessler, Dominic J et al. (2018) A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Mol Ther Methods Clin Dev 9:234-246
Lu, Yi; Tai, Phillip W L; Ai, Jianzhong et al. (2018) Transcriptome Profiling of Neovascularized Corneas Reveals miR-204 as a Multi-target Biotherapy Deliverable by rAAVs. Mol Ther Nucleic Acids 10:349-360

Showing the most recent 10 out of 46 publications